Moderate to severe aortic stenosis: Unraveling risk factors, clinical manifestations, and one-year cardiovascular outcomes

Soleimani, Azam; Karimi, Nastaran; Jamalian, Marjan; Soleimani, Zahra

doi:10.48305/arya.2025.42971.2993

Document Type : Original Article

Authors

¹ Cardiac Rehabilitation Research Center, Isfahan Cardiovascular Research Institute, Isfahan University of Medical Sciences. Isfahan, Iran

² Chamran Cardiovascular Medical and Research Hospital, Isfahan University of Medical Sciences, Isfahan, Iran

³ Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

10.48305/arya.2025.42971.2993

Abstract

BACKGROUND: Aortic stenosis (AS), a progressively degenerative cardiac condition, poses a substantial burden on morbidity and mortality. This study responds to the scarcity of comprehensive data on moderate to severe AS, focusing on risk factors, clinical manifestations, and one-year outcomes.
METHODS: A retrospective cross-sectional study was conducted at Chamran Hospital (2021–2022) involving 97 patients with moderate-to-severe AS. Exclusion criteria included infiltrative diseases, radiotherapy history, cardiogenic shock, ejection fraction <20%, fever, sepsis, and active infections. Data were collected using a standardized checklist with three sections: baseline demographics and risk factors, echocardiographic parameters, and outcomes (in-hospital events, surgical aortic valve replacement [AVR], and one-year mortality).
RESULTS: Among the patients, 29 (29.9%) were classified as moderate AS and the remainder were severe AS. Severe AS patients exhibited higher systolic pulmonary artery pressure (sPAP) and higher prevalence of moderate to severe diastolic dysfunction and three-vessel disease (3VD). Echocardiographic parameters such as mean pressure gradient (MG), peak velocity (PV), and high sPAP were related to the severity of AS (moderate to severe) by odds ratios of 1.13, 6.09, and 1.15 folds, respectively.
CONCLUSION: AS imposes a significant burden of cardiovascular risk on the population. Patients with severe AS showed higher prevalence of increased filling pressures, moderate to severe diastolic dysfunction, 3VD, and higher sPAP compared with the moderate group, with no difference in clinical presentation and one-year outcome.

Keywords

References

1. Eugène M, Duchnowski P, Prendergast B, Wendler O, Laroche C, Monin JL, et al. Contemporary Management of Severe Symptomatic Aortic Stenosis. J Am Coll Cardiol. 2021 Nov 30;78(22):2131-43. https://doi.org/10.1016/j.jacc.2021.09.864

2. Otto CM, Prendergast B. Aortic-valve stenosis--from patients at risk to severe valve obstruction. N Engl J Med. 2014 Aug 21;371(8):744-56. https://doi.org/10.1056/nejmra1313875

3. Danielsen R, Aspelund T, Harris TB, Gudnason V. The prevalence of aortic stenosis in the elderly in Iceland and predictions for the coming decades: the AGES-Reykjavík study. Int J Cardiol. 2014 Oct 20;176(3):916-22. https://doi.org/10.1016/j.ijcard.2014.08.053

4. Martinsson A, Li X, Andersson C, Nilsson J, Smith JG, Sundquist K. Temporal trends in the incidence and prognosis of aortic stenosis: a nationwide study of the Swedish population. Circulation. 2015 Mar 17;131(11):988-94. https://doi.org/10.1161/circulationaha.114.012906

5. Arabloo J, Omidi N, Rezapour A, Sarabi Asiabar A, Mojtaba Ghorashi S, Azari S. The burden of nonrheumatic valvular heart diseases in Iran between 1990 and 2017: Results from the global burden of disease study 2017. Int J Cardiol Heart Vasc. 2022 Jan 17;39:100956. https://doi.org/10.1016/j.ijcha.2022.100956

6. Chen JH, Simmons CA. Cell-matrix interactions in the pathobiology of calcific aortic valve disease: critical roles for matricellular, matricrine, and matrix mechanics cues. Circ Res. 2011 Jun 10;108(12):1510-24. https://doi.org/10.1161/circresaha.110.234237

7. Myasoedova VA, Ravani AL, Frigerio B, Valerio V, Moschetta D, Songia P, et al. Novel pharmacological targets for calcific aortic valve disease: Prevention and treatments. Pharmacol Res. 2018 Oct;136:74-82. https://doi.org/10.1016/j.phrs.2018.08.020

8. Demir B, Caglar IM, Ugurlucan M, Ozde C, Tureli HO, Cifci S, et al. The relationship between severity of calcific aortic stenosis and serum uric acid levels. Angiology. 2012 Nov;63(8):603-8. https://doi.org/10.1177/0003319711433198

9. Lindman BR, Clavel MA, Mathieu P, Iung B, Lancellotti P, Otto CM, et al. Calcific aortic stenosis. Nat Rev Dis Primers. 2016 Mar 3;2:16006. https://doi.org/10.1038/nrdp.2016.6

10. Wypasek E, Natorska J, Mazur P, Kopytek M, Gawęda B, Kapusta P, et al. Effects of rivaroxaban and dabigatran on local expression of coagulation and inflammatory factors within human aortic stenotic valves. Vascul Pharmacol. 2020 Jul;130:106679. https://doi.org/10.1016/j.vph.2020.106679

11. Breyne J, Juthier F, Corseaux D, Marechaux S, Zawadzki C, Jeanpierre E, et al. Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis. 2010 Dec;213(2):369-76. https://doi.org/10.1016/j.atherosclerosis.2010.07.047

12. Natorska J, Marek G, Hlawaty M, Sadowski J, Tracz W, Undas A. Fibrin presence within aortic valves in patients with aortic stenosis: association with in vivo thrombin generation and fibrin clot properties. Thromb Haemost. 2011 Feb;105(2):254-60. https://doi.org/10.1160/th10-09-0612

13. Ahn Y, Choi SJ, Lim S, Kim JB, Song J-M, Kang D-H, et al. Classification of severe aortic stenosis and outcomes after aortic valve replacement. Sci Rep. 2022 May 7;12(1):7506. https://doi.org/10.1038/s41598-022-11491-3

14. Rana M. Aortic Valve Stenosis: Diagnostic Approaches and Recommendations of the 2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease -A Review of the Literature. Cardiol Cardiovasc Med. 2022 Jun;6(3):315-324. https://doi.org/10.26502/fccm.92920267

15. Frank S, Johnson A, Ross J Jr. Natural history of valvular aortic stenosis. Br Heart J. 1973 Jan;35(1):41-6. https://doi.org/10.1136/hrt.35.1.41

16. Chizner MA, Pearle DL, deLeon AC Jr. The natural history of aortic stenosis in adults. Am Heart J. 1980 Apr;99(4):419-24. https://doi.org/10.1016/0002-8703(80)90375-0

17. Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve disease. Eur Heart J. 1987 May;8(5):471-83. https://doi.org/10.1093/oxfordjournals.eurheartj.a062307

18. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. Eur Heart J. 1988 Apr;9 Suppl E:57-64. https://doi.org/10.1093/eurheartj/9.suppl_e.57

19. Martins A, Alves Da Silva P, Brito J, Valente-Silva B, Oliveira C, Garcia B, et al. Moderate aortic stenosis: not as benign as it seems. Eur Heart J Cardiovasc Imaging. 2023;24(Suppl 1):jead119.413. https://doi.org/10.1093/ehjci/jead119.413

20. Hita A, Baratta S, Vaccarino G, Navia J, Olano D, Telayna JM, et al. Severe aortic stenosis with preserved ejection fraction and evidence of impairment in structure, myocardial strain and ventricular function: A new contribution to clinical decision making. Cardiol J. 2015;22(6):613-21. https://doi.org/10.5603/cj.a2015.0034

21. Schwartzenberg S, Vatury M, Wiessman M, Shechter A, Morelli O, Ofek H, et al. Severe aortic stenosis echocardiographic thresholds revisited. Echocardiography. 2021 Dec;38(12):2016-24. https://doi.org/10.1111/echo.15241

22. Badiani S, Bhattacharyya S, Aziminia N, Treibel TA, Lloyd G. Moderate Aortic Stenosis: What is it and When Should We Intervene? Interv Cardiol. 2021 May 27;16:e09. https://doi.org/10.15420/icr.2021.04

23. Luçon A, Oger E, Bedossa M, Boulmier D, Verhoye JP, Eltchaninoff H, et al. Prognostic implications of pulmonary hypertension in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation: study from the FRANCE 2 Registry. Circ Cardiovasc Interv. 2014 Apr;7(2):240-7. https://doi.org/10.1161/circinterventions.113.000482

24. Hess OM, Villari B, Krayenbuehl HP. Diastolic dysfunction in aortic stenosis. Circulation. 1993 May;87(5 Suppl):IV73-6.

25. Amanullah MR, Pio SM, Sin KY, Marsan NA, Ding ZP, Stassen J, et al. Factors Affecting Rate of Progression of Aortic Stenosis and Its Impact on Outcomes. Am J Cardiol. 2022 Dec 15;185:53-62. https://doi.org/10.1016/j.amjcard.2022.09.016

26. Carabello BA. Introduction to aortic stenosis. Circ Res. 2013 Jul 5;113(2):179-85. https://doi.org/10.1161/circresaha.113.300156

27. Nishizaki Y, Daimon M, Miyazaki S, Suzuki H, Kawata T, Miyauchi K, et al. Clinical factors associated with classical symptoms of aortic valve stenosis. J Heart Valve Dis. 2013 May;22(3):287-94.

28. Généreux P, Sharma RP, Cubeddu RJ, Aaron L, Abdelfattah OM, Koulogiannis KP, et al. The Mortality Burden of Untreated Aortic Stenosis. J Am Coll Cardiol. 2023 Nov 28;82(22):2101-09. https://doi.org/10.1016/j.jacc.2023.09.796

29. Coisne A, Scotti A, Latib A, Montaigne D, Ho EC, Ludwig S, et al. Impact of Moderate Aortic Stenosis on Long-Term Clinical Outcomes: A Systematic Review and Meta-Analysis. JACC Cardiovasc Interv. 2022 Aug 22;15(16):1664-74. https://doi.org/10.1016/j.jcin.2022.06.022

ARYA Atherosclerosis Journal

Moderate to severe aortic stenosis: Unraveling risk factors, clinical manifestations, and one-year cardiovascular outcomes

References

References

Volume 21, Issue 5
May and June 2025
Pages 42-50

Moderate to severe aortic stenosis: Unraveling risk factors, clinical manifestations, and one-year cardiovascular outcomes

References

References

Volume 21, Issue 5May and June 2025Pages 42-50

Volume 21, Issue 5
May and June 2025
Pages 42-50